These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33167720)

  • 1. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring
    Pan W; Zhao X; Shi W; Jiang Z; Xiao H
    Leuk Lymphoma; 2020 Nov; 61(11):2756-2759. PubMed ID: 33167720
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.
    Wang S; Wu Z; Li T; Li Y; Wang W; Hao Q; Xie X; Wan D; Jiang Z; Wang C; Liu Y
    Sci Rep; 2020 Jul; 10(1):12152. PubMed ID: 32699322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
    Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
    Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
    Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
    Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
    Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Wu X; Zhang J; Chen Q; Zhou L; Li M; Qiu H; Sun A; Wu D
    Br J Haematol; 2020 Jun; 189(5):e200-e204. PubMed ID: 32242923
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
    Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
    Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
    Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
    Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
    Zhu HH; Qian JJ; Sun WJ; You LS; Wang QQ; Naranmandura H; Jin J
    Am J Hematol; 2020 Mar; 95(3):E55-E57. PubMed ID: 31907961
    [No Abstract]   [Full Text] [Related]  

  • 19. Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
    Flores-Jiménez JA; Pimentel-Morales MA; González-Ramella O; Vega-Cortés D; Zambrano-Velarde MÁ
    J Adolesc Young Adult Oncol; 2019 Aug; 8(4):481-483. PubMed ID: 30835153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
    Pfeiffer T; Li Y; Ashcraft E; Karol SE; Rubnitz JE; Epperly R; Madden R; Mamcarz E; Obeng E; Qudeimat A; Sharma A; Srinivasan A; Suliman A; Talleur AC; Velasquez MP; Gottschalk S; Triplett BM; Naik S
    Bone Marrow Transplant; 2023 Mar; 58(3):328-331. PubMed ID: 36443431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.